2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol;hydron;dichloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2-[4-(3-benzo[b][1]benzazepin-11-ylpropyl)piperazin-1-yl]ethanol;hydron;dichloride
• 化学式: C23H31Cl2N3O
• 分子量: 436.4
• InChiKey: DLTOEESOSYKJBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.15
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  30
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• High throughput cell-based screening for aptamers
  申请人：MeiraGTx UK II Limited

  公开号：US11371077B2

  公开（公告）日：2022-06-28

  The invention provides eukaryotic cell-based screening methods to identify an aptamer that specifically binds a ligand, or a ligand that specifically binds an aptamer, using a polynucleotide cassette for the regulation of the expression of a reporter gene where the polynucleotide cassette contains a riboswitch in the context of a 5′ intron-alternative exon-3′ intron. The riboswitch comprises an effector region and an aptamer such that when the aptamer binds a ligand, reporter gene expression occurs.

  本发明提供了基于真核细胞的筛选方法，利用多核苷酸盒鉴定特异性结合配体的适配体，或特异性结合适配体的配体，以调控报告基因的表达，其中多核苷酸盒在5′内含子-替代外显子-3′内含子的上下文中含有核糖开关。核糖开关包括效应区和适配体，当适配体与配体结合时，报告基因就会表达。
• COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT
  申请人：Institut Gustave Roussy

  公开号：EP2561088A1

  公开（公告）日：2013-02-27
• Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
  申请人：Institut Gustave Roussy

  公开号：EP2806034B1

  公开（公告）日：2017-06-28
• HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS
  申请人：Meiragtx UK II Limited

  公开号：EP3494229A2

  公开（公告）日：2019-06-12
• Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins
  申请人：Sem Daniel S.

  公开号：US20100304998A1

  公开（公告）日：2010-12-02

  Disclosed herein are methods related to drug development. The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and fewer side effects than the existing drug.